{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:27:58Z","timestamp":1751358478726,"version":"3.37.3"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007103","name":"Semnan University","doi-asserted-by":"publisher","award":["1614"],"award-info":[{"award-number":["1614"]}],"id":[{"id":"10.13039\/501100007103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-021-02732-4","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T12:02:56Z","timestamp":1637236976000},"page":"742-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach"],"prefix":"10.1007","volume":"24","author":[{"given":"S.","family":"Arab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-9116","authenticated-orcid":false,"given":"F.","family":"Hasannejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"issue":"7","key":"2732_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/neuonc\/nou087","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a \u201cstate of the science\u201d review. Neuro Oncol. 2014;16(7):896\u2013913.","journal-title":"Neuro Oncol"},{"issue":"10","key":"2732_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"12","key":"2732_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/brainsci7120166","volume":"7","author":"M Lara-Velazquez","year":"2017","unstructured":"Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, Vazquez-Ramos C, Mahato D, Tavanaiepour D, et al. Advances in brain tumor surgery for glioblastoma in adults. Brain Sci. 2017;7(12):166.","journal-title":"Brain Sci"},{"issue":"12","key":"2732_CR4","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3390\/ijms18122544","volume":"18","author":"J Wijaya","year":"2017","unstructured":"Wijaya J, Fukuda Y, Schuetz JD. Obstacles to brain tumor therapy: key ABC transporters. Int J Mol Sci. 2017;18(12):2544.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2732_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-019-0614-0","volume":"7","author":"V Chandramohan","year":"2019","unstructured":"Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu Y-R, et al. Improved efficacy against malignant brain tumors with EGFRwt\/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019;7(1):142.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2732_CR6","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.14694\/EdBook_AM.2013.33.e91","volume":"33","author":"SM Ansell","year":"2013","unstructured":"Ansell SM, Vonderheide RH. Cellular composition of the tumor microenvironment. Am Soc Clin Oncol Educ Book. 2013;33(1):e91\u20137.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2732_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fimmu.2018.00563","volume":"9","author":"X Qu","year":"2018","unstructured":"Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: a cross talk. Front Immunol. 2018;9:563.","journal-title":"Front Immunol"},{"issue":"6","key":"2732_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Vizi ES, Hask\u00f3 G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19(6):355\u201367.","journal-title":"Trends Mol Med"},{"issue":"7","key":"2732_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1586\/1744666X.2014.915739","volume":"10","author":"S Muller-Haegele","year":"2014","unstructured":"Muller-Haegele S, Muller L, Whiteside TL. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol. 2014;10(7):897\u2013914.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2732_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2012.04623.x","volume":"171","author":"F Regateiro","year":"2013","unstructured":"Regateiro F, Cobbold S, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol. 2013;171(1):1\u20137.","journal-title":"Clin Exp Immunol"},{"key":"2732_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","volume":"29","author":"B Allard","year":"2016","unstructured":"Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol. 2016;29:7\u201316.","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"2732_CR12","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.drudis.2017.06.005","volume":"22","author":"L Antonioli","year":"2017","unstructured":"Antonioli L, Novitskiy SV, Sachsenmeier KF, Fornai M, Blandizzi C, Hask\u00f3 G. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov Today. 2017;22(11):1686\u201396.","journal-title":"Drug Discov Today"},{"issue":"3","key":"2732_CR13","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/jcp.25873","volume":"233","author":"MH Kazemi","year":"2018","unstructured":"Kazemi MH, RaoofiMohseni S, Hojjat-Farsangi M, Anvari E, Ghalamfarsa G, Mohammadi H, et al. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. J Cell Physiol. 2018;233(3):2032\u201357.","journal-title":"J Cell Physiol"},{"issue":"10","key":"2732_CR14","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","volume":"23","author":"JP Thakkar","year":"2014","unstructured":"Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Prev Biomark. 2014;23(10):1985\u201396.","journal-title":"Cancer Epidemiol Prev Biomark"},{"issue":"3","key":"2732_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","volume":"49","author":"MD Walker","year":"1978","unstructured":"Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, et al. Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978;49(3):333\u201343.","journal-title":"J Neurosurg"},{"issue":"5","key":"2732_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459\u201366.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2732_CR17","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","volume":"20","author":"ME Davis","year":"2016","unstructured":"Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5):S2.","journal-title":"Clin J Oncol Nurs"},{"key":"2732_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-6413-2-19","volume":"2","author":"S Schultz","year":"2005","unstructured":"Schultz S, Pinsky GS, Wu NC, Chamberlain MC, Rodrigo AS, Martin SE. Fine needle aspiration diagnosis of extracranial glioblastoma multiforme: case report and review of the literature. Cytojournal. 2005;2:19.","journal-title":"Cytojournal"},{"issue":"8","key":"2732_CR19","first-page":"712","volume":"11","author":"AG Linkous","year":"2011","unstructured":"Linkous AG, Yazlovitskaya EM. Angiogenesis in glioblastoma multiforme: navigating the maze. Anti-Cancer Agents Med Chem (Formerly Curr Med Chem Anti-Cancer Agents). 2011;11(8):712\u20138.","journal-title":"Anti-Cancer Agents Med Chem (Formerly Curr Med Chem Anti-Cancer Agents)"},{"issue":"6","key":"2732_CR20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3171\/jns.1996.85.6.1078","volume":"85","author":"AM Rojiani","year":"1996","unstructured":"Rojiani AM, Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J Neurosurg. 1996;85(6):1078\u201384.","journal-title":"J Neurosurg"},{"issue":"24","key":"2732_CR21","doi-asserted-by":"publisher","first-page":"12908","DOI":"10.18632\/oncotarget.2679","volume":"5","author":"W Yan","year":"2014","unstructured":"Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, et al. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 2014;5(24):12908.","journal-title":"Oncotarget"},{"issue":"9","key":"2732_CR22","doi-asserted-by":"publisher","first-page":"7318","DOI":"10.18632\/oncotarget.3440","volume":"6","author":"R Li","year":"2015","unstructured":"Li R, Li H, Yan W, Yang P, Bao Z, Zhang C, et al. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget. 2015;6(9):7318.","journal-title":"Oncotarget"},{"issue":"6","key":"2732_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","volume":"116","author":"J Balss","year":"2008","unstructured":"Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597\u2013602.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2732_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","volume":"174","author":"T Watanabe","year":"2009","unstructured":"Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149\u201353.","journal-title":"Am J Pathol"},{"issue":"8","key":"2732_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"1","key":"2732_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98\u2013110.","journal-title":"Cancer Cell"},{"issue":"1","key":"2732_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1752-1947-3-87","volume":"3","author":"SE Lakhan","year":"2009","unstructured":"Lakhan SE, Harle L. Difficult diagnosis of brainstem glioblastoma multiforme in a woman: a case report and review of the literature. J Med Case Rep. 2009;3(1):87.","journal-title":"J Med Case Rep"},{"issue":"5","key":"2732_CR28","first-page":"307","volume":"18","author":"K Urba\u0144ska","year":"2014","unstructured":"Urba\u0144ska K, Soko\u0142owska J, Szmidt M, Sysa P. Glioblastoma multiforme\u2014an overview. Contemp Oncol. 2014;18(5):307.","journal-title":"Contemp Oncol"},{"issue":"5","key":"2732_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/030089160609200507","volume":"92","author":"C Ulutin","year":"2006","unstructured":"Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, et al. Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori J. 2006;92(5):407\u201311.","journal-title":"Tumori J"},{"issue":"2","key":"2732_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0360-3016(93)90203-8","volume":"26","author":"J Simpson","year":"1993","unstructured":"Simpson J, Horton J, Scott C, Curran W, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26(2):239\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2732_CR31","doi-asserted-by":"publisher","first-page":"9540","DOI":"10.18632\/oncotarget.23476","volume":"9","author":"X Cai","year":"2018","unstructured":"Cai X, Sughrue ME. Glioblastoma: new therapeutic strategies to address cellular and genomic complexity. Oncotarget. 2018;9(10):9540.","journal-title":"Oncotarget"},{"key":"2732_CR32","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"13","author":"K Graham","year":"2018","unstructured":"Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomed. 2018;13:6049.","journal-title":"Int J Nanomed"},{"issue":"49","key":"2732_CR33","doi-asserted-by":"publisher","first-page":"85516","DOI":"10.18632\/oncotarget.20231","volume":"8","author":"K Kawaguchi","year":"2017","unstructured":"Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Kiyuna T, et al. Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2017;8(49):85516.","journal-title":"Oncotarget"},{"issue":"50","key":"2732_CR34","doi-asserted-by":"publisher","first-page":"87554","DOI":"10.18632\/oncotarget.20848","volume":"8","author":"J Shi","year":"2017","unstructured":"Shi J, Dong B, Zhou P, Guan W, Peng Y. Functional network analysis of gene-phenotype connectivity associated with temozolomide. Oncotarget. 2017;8(50):87554.","journal-title":"Oncotarget"},{"issue":"2","key":"2732_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/sj.onc.1209785","volume":"26","author":"W Roos","year":"2007","unstructured":"Roos W, Batista LFZ, Naumann S, Wick W, Weller M, Menck CFM, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26(2):186\u201397.","journal-title":"Oncogene"},{"issue":"10","key":"2732_CR36","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, De Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"key":"2732_CR37","volume-title":"Current trends in glioblastoma treatment. Brain tumors\u2014an update","author":"LG Tataranu","year":"2018","unstructured":"Tataranu LG, Ciubotaru V, Cazac TL, Alexandru O, Purcaru OS, Tache DE, et al. Current trends in glioblastoma treatment. Brain tumors\u2014an update. New York: IntechOpen; 2018."},{"issue":"2","key":"2732_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5306\/wjco.v5.i2.142","volume":"5","author":"EW Larson","year":"2014","unstructured":"Larson EW, Peterson HE, Lamoreaux WT, MacKay AR, Fairbanks RK, Call JA, et al. Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma. World J Clin Oncol. 2014;5(2):142.","journal-title":"World J Clin Oncol"},{"issue":"17","key":"2732_CR39","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1002\/cncr.27372","volume":"118","author":"T Koga","year":"2012","unstructured":"Koga T, Maruyama K, Tanaka M, Ino Y, Saito N, Nakagawa K, et al. Extended field stereotactic radiosurgery for recurrent glioblastoma. Cancer. 2012;118(17):4193\u2013200.","journal-title":"Cancer"},{"issue":"1","key":"2732_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1040-8428(01)00179-2","volume":"43","author":"B Hildebrandt","year":"2002","unstructured":"Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33\u201356.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2732_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/brainsci8010015","volume":"8","author":"M Paolillo","year":"2018","unstructured":"Paolillo M, Boselli C, Schinelli S. Glioblastoma under siege: an overview of current therapeutic strategies. Brain Sci. 2018;8(1):15.","journal-title":"Brain Sci"},{"key":"2732_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biopha.2015.12.014","volume":"77","author":"F Pourgholi","year":"2016","unstructured":"Pourgholi F, Farhad J-N, Kafil HS, Yousefi M. Nanoparticles: novel vehicles in treatment of glioblastoma. Biomed Pharmacother. 2016;77:98\u2013107.","journal-title":"Biomed Pharmacother"},{"key":"2732_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fphys.2018.00170","volume":"9","author":"E Ozdemir-Kaynak","year":"2018","unstructured":"Ozdemir-Kaynak E, Qutub AA, Yesil-Celiktas O. Advances in glioblastoma multiforme treatment: new models for nanoparticle therapy. Front Physiol. 2018;9:170.","journal-title":"Front Physiol"},{"issue":"1","key":"2732_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/neuonc\/nop007","volume":"12","author":"H Colman","year":"2010","unstructured":"Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010;12(1):49\u201357.","journal-title":"Neuro Oncol"},{"issue":"31","key":"2732_CR45","doi-asserted-by":"publisher","first-page":"30968","DOI":"10.18632\/oncotarget.5038","volume":"6","author":"R Li","year":"2015","unstructured":"Li R, Chen X, You Y, Wang X, Liu Y, Hu Q, et al. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics. Oncotarget. 2015;6(31):30968.","journal-title":"Oncotarget"},{"issue":"3","key":"2732_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4081\/ejtm.2019.8209","volume":"29","author":"A Alinezhad","year":"2019","unstructured":"Alinezhad A, Jafari F. Novel management of glioma by molecular therapies, a review article. Eur J Transl Myol. 2019;29(3):202\u201309.","journal-title":"Eur J Transl Myol"},{"issue":"4","key":"2732_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18388\/abp.2012_2105","volume":"59","author":"R Sadej","year":"2012","unstructured":"Sadej R, Skladanowski AC. Dual, enzymatic and non-enzymatic, function of ecto-5'-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol. 2012;59(4):1\u20138.","journal-title":"Acta Biochim Pol."},{"issue":"1","key":"2732_CR48","first-page":"16","volume":"23","author":"V TaghdiriNooshabadi","year":"2021","unstructured":"TaghdiriNooshabadi V, Arab S, Taghdiri NZ. Exosomes: novel bio-inspired nanocarriers for efficient targeting of glioblastoma tumor cells. J Babol Univ Med Sci. 2021;23(1):16\u201322.","journal-title":"J Babol Univ Med Sci"},{"issue":"2","key":"2732_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","volume":"127","author":"IP Kaur","year":"2008","unstructured":"Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2):97\u2013109.","journal-title":"J Control Release"},{"issue":"40","key":"2732_CR50","doi-asserted-by":"publisher","first-page":"66889","DOI":"10.18632\/oncotarget.17976","volume":"8","author":"Z Belhadj","year":"2017","unstructured":"Belhadj Z, Zhan C, Ying M, Wei X, Xie C, Yan Z, et al. Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment. Oncotarget. 2017;8(40):66889.","journal-title":"Oncotarget"},{"issue":"12","key":"2732_CR51","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1021\/bc200406n","volume":"22","author":"J Jin","year":"2011","unstructured":"Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 2011;22(12):2568\u201372.","journal-title":"Bioconjug Chem"},{"key":"2732_CR52","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fphar.2019.00772","volume":"10","author":"C Bailly","year":"2019","unstructured":"Bailly C, Vidal A, Bonnemaire C, Kraeber-Bod\u00e9r\u00e9 F, Ch\u00e9rel M, Pallardy A, et al. Potential for nuclear medicine therapy for glioblastoma treatment. Front Pharmacol. 2019;10:1\u20139.","journal-title":"Front Pharmacol"},{"key":"2732_CR53","volume-title":"Current therapeutic strategies for glioblastoma","author":"J Rossignol","year":"2020","unstructured":"Rossignol J, Srinageshwar B, Dunbar GL. Current therapeutic strategies for glioblastoma. Basel: Multidisciplinary Digital Publishing Institute; 2020."},{"issue":"5","key":"2732_CR54","first-page":"1383","volume":"60","author":"L Frederick","year":"2000","unstructured":"Frederick L, Wang X-Y, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Can Res. 2000;60(5):1383\u20137.","journal-title":"Can Res"},{"issue":"1","key":"2732_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15321819.2016.1209217","volume":"38","author":"F Serban","year":"2017","unstructured":"Serban F, Daianu O, Tataranu LG, Artene S-A, Emami G, Georgescu AM, et al. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma. J Immunoassay Immunochem. 2017;38(1):21\u201333.","journal-title":"J Immunoassay Immunochem"},{"key":"2732_CR56","first-page":"3767","volume":"8","author":"F Serban","year":"2015","unstructured":"Serban F, Artene S-A, Georgescu AM, Purcaru SO, Tache DE, Alexandru O, et al. Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker. Onco Targets Ther. 2015;8:3767.","journal-title":"Onco Targets Ther"},{"issue":"23","key":"2732_CR57","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1242\/jcs.190546","volume":"129","author":"KS Midwood","year":"2016","unstructured":"Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. J Cell Sci. 2016;129(23):4321\u20137.","journal-title":"J Cell Sci"},{"issue":"5","key":"2732_CR58","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1517\/14712598.6.5.539","volume":"6","author":"WR Shapiro","year":"2006","unstructured":"Shapiro WR, Carpenter SP, Roberts K, Shan JS. 131I-chTNT-1\/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther. 2006;6(5):539\u201345.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"2732_CR59","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2217\/fon.12.58","volume":"8","author":"A Hdeib","year":"2012","unstructured":"Hdeib A, Sloan A. Targeted radioimmunotherapy: the role of 131I-chTNT-1\/B mAb (Cotara\u00ae) for treatment of high-grade gliomas. Future Oncol. 2012;8(6):659\u201369.","journal-title":"Future Oncol"},{"issue":"6","key":"2732_CR60","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1227\/01.NEU.0000159649.71890.30","volume":"56","author":"SJ Patel","year":"2005","unstructured":"Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery. 2005;56(6):1243\u201353.","journal-title":"Neurosurgery"},{"key":"2732_CR61","doi-asserted-by":"publisher","first-page":"201","DOI":"10.7150\/thno\/v01p0201","volume":"1","author":"Z Liu","year":"2011","unstructured":"Liu Z, Wang F, Chen X. Integrin targeted delivery of radiotherapeutics. Theranostics. 2011;1:201.","journal-title":"Theranostics"},{"issue":"2","key":"2732_CR62","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2014.12.044","volume":"358","author":"A Zanotto-Filho","year":"2015","unstructured":"Zanotto-Filho A, Braganhol E, Klafke K, Figueir\u00f3 F, Terra SR, Paludo FJ, et al. Autophagy inhibition improves the efficacy of curcumin\/temozolomide combination therapy in glioblastomas. Cancer Lett. 2015;358(2):220\u201331.","journal-title":"Cancer Lett"},{"key":"2732_CR63","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fonc.2012.00098","volume":"2","author":"M Nakada","year":"2012","unstructured":"Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J-I. The strategy for enhancing temozolomide against malignant glioma. Front Oncol. 2012;2:98.","journal-title":"Front Oncol"},{"issue":"2","key":"2732_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4081\/oncol.2019.417","volume":"13","author":"S Bahadur","year":"2019","unstructured":"Bahadur S, Sahu AK, Baghel P, Saha S. Current promising treatment strategy for glioblastoma multiform: a review. Oncol Rev. 2019;13(2):114\u201324.","journal-title":"Oncol Rev"},{"issue":"2","key":"2732_CR65","first-page":"105","volume":"1","author":"CE Pelloski","year":"2007","unstructured":"Pelloski CE, Gilbert MR. Current treatment options in adult glioblastoma. J Curr Treat Options Adult Glioblastoma. 2007;1(2):105\u201309.","journal-title":"J Curr Treat Options Adult Glioblastoma."},{"issue":"7","key":"2732_CR66","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.7150\/thno.40298","volume":"10","author":"J Yang","year":"2020","unstructured":"Yang J, Shi Z, Liu R, Wu Y, Zhang X. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. Theranostics. 2020;10(7):3223.","journal-title":"Theranostics"},{"issue":"1","key":"2732_CR67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jconrel.2011.05.008","volume":"154","author":"L Guo","year":"2011","unstructured":"Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release. 2011;154(1):93\u2013102.","journal-title":"J Control Release"},{"key":"2732_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2016.07.032","volume":"238","author":"CL Esposito","year":"2016","unstructured":"Esposito CL, Nuzzo S, Kumar SA, Rienzo A, Lawrence CL, Pallini R, et al. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells. J Control Release. 2016;238:43\u201357.","journal-title":"J Control Release"},{"issue":"7412","key":"2732_CR69","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","volume":"488","author":"J Chen","year":"2012","unstructured":"Chen J, Li Y, Yu T-S, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522\u20136.","journal-title":"Nature"},{"issue":"7","key":"2732_CR70","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1021\/acs.nanolett.8b00390","volume":"18","author":"H Lopez-Bertoni","year":"2018","unstructured":"Lopez-Bertoni H, Kozielski KL, Rui Y, Lal B, Vaughan H, Wilson DR, et al. Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival. Nano Lett. 2018;18(7):4086\u201394.","journal-title":"Nano Lett"},{"issue":"46","key":"2732_CR71","doi-asserted-by":"publisher","first-page":"1703967","DOI":"10.1002\/adfm.201703967","volume":"27","author":"Z Lu","year":"2017","unstructured":"Lu Z, Li Y, Shi Y, Li Y, Xiao Z, Zhang X. Traceable nanoparticles with spatiotemporally controlled release ability for synergistic glioblastoma multiforme treatment. Adv Func Mater. 2017;27(46):1703967.","journal-title":"Adv Func Mater"},{"issue":"8","key":"2732_CR72","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"2732_CR73","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/bjc.2014.209","volume":"110","author":"A Hottinger","year":"2014","unstructured":"Hottinger A, Aissa AB, Espeli V, Squiban D, Dunkel N, Vargas M, et al. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer. 2014;110(11):2655\u201361.","journal-title":"Br J Cancer"},{"issue":"4","key":"2732_CR74","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.20114","volume":"61","author":"P Agostinis","year":"2011","unstructured":"Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clinicians. 2011;61(4):250\u201381.","journal-title":"CA Cancer J Clinicians."},{"issue":"9","key":"2732_CR75","doi-asserted-by":"publisher","first-page":"889","DOI":"10.7150\/thno.4754","volume":"2","author":"H Benachour","year":"2012","unstructured":"Benachour H, S\u00e8ve A, Bastogne T, Frochot C, Vanderesse R, Jasniewski J, et al. Multifunctional peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI. Theranostics. 2012;2(9):889.","journal-title":"Theranostics"},{"issue":"1","key":"2732_CR76","doi-asserted-by":"publisher","first-page":"1600106","DOI":"10.1002\/advs.201600106","volume":"4","author":"D Luo","year":"2017","unstructured":"Luo D, Carter KA, Miranda D, Lovell JF. Chemophototherapy: an emerging treatment option for solid tumors. Adv Sci. 2017;4(1):1600106.","journal-title":"Adv Sci"},{"issue":"6","key":"2732_CR77","doi-asserted-by":"publisher","first-page":"762","DOI":"10.7150\/thno.14988","volume":"6","author":"L Zou","year":"2016","unstructured":"Zou L, Wang H, He B, Zeng L, Tan T, Cao H, et al. Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics. 2016;6(6):762.","journal-title":"Theranostics"},{"issue":"16","key":"2732_CR78","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.1039\/C9NR01789E","volume":"11","author":"H Zhang","year":"2019","unstructured":"Zhang H, Wang T, Liu H, Ren F, Qiu W, Sun Q, et al. Second near-infrared photodynamic therapy and chemotherapy of orthotopic malignant glioblastoma with ultra-small Cu2\u2212x Se nanoparticles. Nanoscale. 2019;11(16):7600\u20138.","journal-title":"Nanoscale"},{"issue":"1","key":"2732_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06574-7","volume":"9","author":"G Yu","year":"2018","unstructured":"Yu G, Yu S, Saha ML, Zhou J, Cook TR, Yung BC, et al. A discrete organoplatinum (II) metallacage as a multimodality theranostic platform for cancer photochemotherapy. Nat Commun. 2018;9(1):1\u201318.","journal-title":"Nat Commun"},{"issue":"2","key":"2732_CR80","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/neuonc\/nox139","volume":"20","author":"M-C Speranza","year":"2018","unstructured":"Speranza M-C, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, et al. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018;20(2):225\u201335.","journal-title":"Neuro Oncol"},{"issue":"2","key":"2732_CR81","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1083\/jcb.136.2.421","volume":"136","author":"L Airas","year":"1997","unstructured":"Airas L, Niemel\u00e4 J, Salmi M, Puurunen T, Smith DJ, Jalkanen S. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol\u2013linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J Cell Biol. 1997;136(2):421\u201331.","journal-title":"J Cell Biol"},{"issue":"10","key":"2732_CR82","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.bbamcr.2012.08.001","volume":"1823","author":"M Helenius","year":"2012","unstructured":"Helenius M, Jalkanen S, Yegutkin GG. Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids. Biochim Biophys Acta (BBA) Mol Cell Res. 2012;1823(10):1967\u201375.","journal-title":"Biochim Biophys Acta (BBA) Mol Cell Res"},{"issue":"39","key":"2732_CR83","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/onc.2010.292","volume":"29","author":"J Stagg","year":"2010","unstructured":"Stagg J, Smyth M. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29(39):5346\u201358.","journal-title":"Oncogene"},{"issue":"4","key":"2732_CR84","first-page":"1","volume":"2012","author":"F Ghiringhelli","year":"2012","unstructured":"Ghiringhelli F, Bruchard M, Chalmin F, R\u00e9b\u00e9 C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. BioMed Res Int. 2012;2012(4):1\u20139.","journal-title":"BioMed Res Int."},{"issue":"6","key":"2732_CR85","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10585-007-9081-y","volume":"24","author":"X Zhi","year":"2007","unstructured":"Zhi X, Chen S, Zhou P, Shao Z, Wang L, Ou Z, et al. RNA interference of ecto-5\u2032-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metas. 2007;24(6):439\u201348.","journal-title":"Clin Exp Metas"},{"issue":"16","key":"2732_CR86","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1002\/cbic.201200426","volume":"13","author":"DP Heuts","year":"2012","unstructured":"Heuts DP, Weissenborn MJ, Olkhov RV, Shaw AM, Gummadova J, Levy C, et al. Crystal structure of a soluble form of human CD73 with ecto-5\u2032-nucleotidase activity. ChemBioChem. 2012;13(16):2384\u201391.","journal-title":"ChemBioChem"},{"issue":"5","key":"2732_CR87","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.it.2012.02.009","volume":"33","author":"PA Beavis","year":"2012","unstructured":"Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012;33(5):231\u20137.","journal-title":"Trends Immunol"},{"key":"2732_CR88","first-page":"1","volume":"2014","author":"Z-W Gao","year":"2014","unstructured":"Gao Z-W, Dong K, Zhang H-Z. The roles of CD73 in cancer. BioMed Res Int. 2014;2014:1\u20139.","journal-title":"BioMed Res Int."},{"issue":"1","key":"2732_CR89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4161\/onci.1.1.18068","volume":"1","author":"B Zhang","year":"2012","unstructured":"Zhang B. CD73 promotes tumor growth and metastasis. Oncoimmunology. 2012;1(1):67\u201370.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2732_CR90","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1172\/JCI45559","volume":"121","author":"L Wang","year":"2011","unstructured":"Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Investig. 2011;121(6):2371\u201382.","journal-title":"J Clin Investig"},{"issue":"4","key":"2732_CR91","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11302-011-9265-4","volume":"7","author":"SC Robson","year":"2011","unstructured":"Robson SC. Role of CD73 and extracellular adenosine in disease. Purinergic Signal. 2011;7(4):367\u201372.","journal-title":"Purinergic Signal"},{"issue":"12","key":"2732_CR92","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1111\/j.1349-7006.2010.01733.x","volume":"101","author":"X Zhi","year":"2010","unstructured":"Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang S, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 2010;101(12):2561\u20139.","journal-title":"Cancer Sci"},{"issue":"2","key":"2732_CR93","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00441-013-1752-1","volume":"355","author":"L Xiong","year":"2014","unstructured":"Xiong L, Wen Y, Miao X, Yang Z. NT5E and FcGBP as key regulators of TGF-1-induced epithelial\u2013mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. Cell Tissue Res. 2014;355(2):365\u201374.","journal-title":"Cell Tissue Res"},{"issue":"4","key":"2732_CR94","doi-asserted-by":"publisher","first-page":"647","DOI":"10.18388\/abp.2012_2105","volume":"59","author":"R Sadej","year":"2012","unstructured":"Sadej R, Skladanowski AC. Dual, enzymatic and non-enzymatic, function of ecto-5'-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol. 2012;59(4):647\u201352.","journal-title":"Acta Biochim Pol."},{"issue":"3","key":"2732_CR95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00432-007-0292-z","volume":"134","author":"L Wang","year":"2008","unstructured":"Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, et al. Ecto-5\u2032-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol. 2008;134(3):365\u201372.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"2732_CR96","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd2638","volume":"7","author":"G Hask\u00f3","year":"2008","unstructured":"Hask\u00f3 G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759\u201370.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2732_CR97","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0301-0082(02)00155-7","volume":"68","author":"J Ribeiro","year":"2002","unstructured":"Ribeiro J, Sebastiao A, De Mendon\u00e7a A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol. 2002;68(6):377\u201392.","journal-title":"Prog Neurobiol"},{"issue":"8","key":"2732_CR98","doi-asserted-by":"publisher","first-page":"e6784","DOI":"10.1371\/journal.pone.0006784","volume":"4","author":"M Koeppen","year":"2009","unstructured":"Koeppen M, Eckle T, Eltzschig HK. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS ONE. 2009;4(8):e6784.","journal-title":"PLoS ONE"},{"key":"2732_CR99","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3389\/fimmu.2019.00698","volume":"10","author":"S de Leve","year":"2019","unstructured":"de Leve S, Wirsd\u00f6rfer F, Jendrossek V. Targeting the immunomodulatory CD73\/adenosine system to improve the therapeutic gain of radiotherapy. Front Immunol. 2019;10:698.","journal-title":"Front Immunol"},{"issue":"20","key":"2732_CR100","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.1158\/1078-0432.CCR-09-1143","volume":"15","author":"M Mandapathil","year":"2009","unstructured":"Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res. 2009;15(20):6348\u201357.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2732_CR101","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10238-020-00674-9","volume":"21","author":"S Arab","year":"2021","unstructured":"Arab S, Alizadeh A, Asgharzade S. Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment. Clin Exp Med. 2021;21(2):205\u201313.","journal-title":"Clin Exp Med."},{"key":"2732_CR102","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3389\/fimmu.2017.01526","volume":"8","author":"MP de Andrade","year":"2017","unstructured":"de Andrade MP, Coutinho-Silva R, Savio LEB. Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor\u2013host interaction and therapeutic perspectives. Front Immunol. 2017;8:1526.","journal-title":"Front Immunol"},{"key":"2732_CR103","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2016.12.012","volume":"246","author":"F Jadidi-Niaragh","year":"2017","unstructured":"Jadidi-Niaragh F, Atyabi F, Rastegari A, Kheshtchin N, Arab S, Hassannia H, et al. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. J Control Release. 2017;246:46\u201359.","journal-title":"J Control Release"},{"issue":"12","key":"2732_CR104","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hask\u00f3 G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13(12):842\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"2732_CR105","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","volume":"74","author":"C Cekic","year":"2014","unstructured":"Cekic C, Day Y-J, Sag D, Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Can Res. 2014;74(24):7250\u20139.","journal-title":"Can Res"},{"issue":"5","key":"2732_CR106","doi-asserted-by":"publisher","first-page":"e1127496","DOI":"10.1080\/2162402X.2015.1127496","volume":"5","author":"P-O Gaudreau","year":"2016","unstructured":"Gaudreau P-O, Allard B, Turcotte M, Stagg J. CD73-adenosine reduces immune responses and survival in ovarian cancer patients. Oncoimmunology. 2016;5(5):e1127496.","journal-title":"Oncoimmunology."},{"issue":"1","key":"2732_CR107","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1096\/fj.11-190934","volume":"26","author":"B Cs\u00f3ka","year":"2012","unstructured":"Cs\u00f3ka B, Selmeczy Z, Koscs\u00f3 B, N\u00e9meth ZH, Pacher P, Murray PJ, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 2012;26(1):376\u201386.","journal-title":"FASEB J"},{"issue":"11","key":"2732_CR108","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.4049\/jimmunol.1101225","volume":"187","author":"S Ryzhov","year":"2011","unstructured":"Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+ Gr1+ cells. J Immunol. 2011;187(11):6120\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"2732_CR109","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/ATVBAHA.111.226852","volume":"32","author":"G Hask\u00f3","year":"2012","unstructured":"Hask\u00f3 G, Pacher P. Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32(4):865\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2732_CR110","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell. 2016;30(3):391\u2013403.","journal-title":"Cancer Cell"},{"issue":"11","key":"2732_CR111","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1002\/eji.200838651","volume":"38","author":"J Kiss","year":"2008","unstructured":"Kiss J, Jalkanen S, F\u00fcl\u00f6p F, Savunen T, Salmi M. Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors. Eur J Immunol. 2008;38(11):3041\u20139.","journal-title":"Eur J Immunol"},{"issue":"11","key":"2732_CR112","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1084\/jem.20040915","volume":"200","author":"LF Thompson","year":"2004","unstructured":"Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, et al. Crucial role for ecto-5\u2032-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004;200(11):1395\u2013405.","journal-title":"J Exp Med"},{"key":"2732_CR113","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","volume":"10","author":"S Vigano","year":"2019","unstructured":"Vigano S, Alatzoglou D, Irving M, M\u00e9n\u00e9trier-Caux C, Caux C, Romero P, et al. Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front Immunol. 2019;10:1\u201330.","journal-title":"Front Immunol"},{"key":"2732_CR114","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.taap.2016.11.016","volume":"314","author":"E Tak","year":"2017","unstructured":"Tak E, Jung D-H, Kim S-H, Park G-C, Jun DY, Lee J, et al. Protective role of hypoxia-inducible factor-1\u03b1-dependent CD39 and CD73 in fulminant acute liver failure. Toxicol Appl Pharmacol. 2017;314:72\u201381.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"2732_CR115","first-page":"224","volume":"113","author":"HK Eltzschig","year":"2009","unstructured":"Eltzschig HK, K\u00f6hler D, Eckle T, Kong T, Robson SC, Colgan SP. Central role of Sp1-regulated CD39 in hypoxia\/ischemia protection. Blood J Am Soc Hematol. 2009;113(1):224\u201332.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"2732_CR116","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4049\/jimmunol.1100593","volume":"192","author":"T Eckle","year":"2014","unstructured":"Eckle T, Kewley EM, Brodsky KS, Tak E, Bonney S, Gobel M, et al. Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. J Immunol. 2014;192(3):1249\u201356.","journal-title":"J Immunol"},{"issue":"8","key":"2732_CR117","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1096\/fj.13-228551","volume":"27","author":"T Eckle","year":"2013","unstructured":"Eckle T, Hughes K, Ehrentraut H, Brodsky KS, Rosenberger P, Choi DS, et al. Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. FASEB J. 2013;27(8):3078\u201389.","journal-title":"FASEB J"},{"issue":"2","key":"2732_CR118","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00109-012-0988-7","volume":"91","author":"JM Poth","year":"2013","unstructured":"Poth JM, Brodsky K, Ehrentraut H, Grenz A, Eltzschig HK. Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease. J Mol Med. 2013;91(2):183\u201393.","journal-title":"J Mol Med"},{"issue":"5","key":"2732_CR119","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.tips.2018.02.006","volume":"39","author":"SJ Trenfield","year":"2018","unstructured":"Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug development to frontline care. Trends Pharmacol Sci. 2018;39(5):440\u201351.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"2732_CR120","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/carcin\/bgx137","volume":"39","author":"X Bu","year":"2018","unstructured":"Bu X, Kato J, Hong JA, Merino MJ, Schrump DS, Lund FE, et al. CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells. Carcinogenesis. 2018;39(2):242\u201351.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2732_CR121","doi-asserted-by":"publisher","first-page":"1744946","DOI":"10.1080\/2162402X.2020.1744946","volume":"9","author":"I Shevchenko","year":"2020","unstructured":"Shevchenko I, Mathes A, Groth C, Karakhanova S, M\u00fcller V, Utikal J, et al. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. Oncoimmunology. 2020;9(1):1744946.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2732_CR122","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.immuni.2011.12.019","volume":"36","author":"F Chalmin","year":"2012","unstructured":"Chalmin F, Mignot G, Bruchard M, Chevriaux A, V\u00e9gran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity. 2012;36(3):362\u201373.","journal-title":"Immunity"},{"key":"2732_CR123","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.imlet.2018.05.001","volume":"205","author":"D Allard","year":"2019","unstructured":"Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J. Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett. 2019;205:31\u20139.","journal-title":"Immunol Lett"},{"issue":"2","key":"2732_CR124","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.imlet.2015.05.016","volume":"166","author":"Q-G Zhang","year":"2015","unstructured":"Zhang Q-G, Qian J, Zhu Y-C. Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis. Immunol Lett. 2015;166(2):103\u20138.","journal-title":"Immunol Lett"},{"issue":"8","key":"2732_CR125","doi-asserted-by":"publisher","first-page":"e1208875","DOI":"10.1080\/2162402X.2016.1208875","volume":"5","author":"CM Hay","year":"2016","unstructured":"Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016;5(8):e1208875.","journal-title":"Oncoimmunology."},{"issue":"22","key":"2732_CR126","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.3390\/ijms20225698","volume":"20","author":"JH Azambuja","year":"2019","unstructured":"Azambuja JH, Ludwig N, Braganhol E, Whiteside TL. Inhibition of the adenosinergic pathway in cancer rejuvenates innate and adaptive immunity. Int J Mol Sci. 2019;20(22):5698.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2732_CR127","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.4110\/in.2019.19.e23","volume":"19","author":"S Arab","year":"2019","unstructured":"Arab S, Hadjati J. Adenosine blockage in tumor microenvironment and improvement of cancer immunotherapy. Immune Netw. 2019;19(4):e23.","journal-title":"Immune Netw."},{"issue":"6","key":"2732_CR128","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.molmed.2013.02.005","volume":"19","author":"HK Eltzschig","year":"2013","unstructured":"Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol Med. 2013;19(6):345\u201354.","journal-title":"Trends Mol Med"},{"issue":"4","key":"2732_CR129","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41573-020-00109-w","volume":"20","author":"W Ruan","year":"2021","unstructured":"Ruan W, Yuan X, Eltzschig HK. Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021;20(4):287\u2013307.","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"2732_CR130","doi-asserted-by":"publisher","first-page":"e1102","DOI":"10.1038\/cddis.2014.70","volume":"5","author":"A Cauwels","year":"2014","unstructured":"Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis. 2014;5(3):e1102.","journal-title":"Cell Death Dis"},{"issue":"22","key":"2732_CR131","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1523\/JNEUROSCI.1118-18.2019","volume":"39","author":"A Yan","year":"2019","unstructured":"Yan A, Joachims ML, Thompson LF, Miller AD, Canoll PD, Bynoe MS. CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A2B adenosine receptor signaling. J Neurosci. 2019;39(22):4387\u2013402.","journal-title":"J Neurosci"},{"issue":"6","key":"2732_CR132","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2174\/1566524020666201120142953","volume":"21","author":"VT Nooshabadi","year":"2021","unstructured":"Nooshabadi VT, Arab S. Targeting tumor-derived exosomes expressing CD73: new opportunities in the pathogenesis and treatment of cancer. Curr Mol Med. 2021;21(6):476\u201383.","journal-title":"Curr Mol Med."},{"issue":"4","key":"2732_CR133","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells6040045","volume":"6","author":"AR Monteiro","year":"2017","unstructured":"Monteiro AR, Hill R, Pilkington GJ, Madureira PA. The role of hypoxia in glioblastoma invasion. Cells. 2017;6(4):45.","journal-title":"Cells"},{"key":"2732_CR134","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3389\/fphar.2018.00879","volume":"9","author":"E Alphand\u00e9ry","year":"2018","unstructured":"Alphand\u00e9ry E. Glioblastoma treatments: an account of recent industrial developments. Front Pharmacol. 2018;9:879.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2732_CR135","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2353\/ajpath.2010.091021","volume":"177","author":"EE Bar","year":"2010","unstructured":"Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol. 2010;177(3):1491\u2013502.","journal-title":"Am J Pathol"},{"key":"2732_CR136","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3389\/fncel.2014.00418","volume":"8","author":"LG Dubois","year":"2014","unstructured":"Dubois LG, Campanati L, Righy C, D\u2019Andrea-Meira I, Spohr Tclds, Porto-Carreiro I, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. 2014;8:418.","journal-title":"Front Cell Neurosci."},{"key":"2732_CR137","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2018.00249","volume":"8","author":"A Lo Dico","year":"2018","unstructured":"Lo Dico A, Martelli C, Diceglie C, Lucignani G, Ottobrini L. Hypoxia-inducible factor-1\u03b1 activity as a switch for glioblastoma responsiveness to temozolomide. Front Oncol. 2018;8:249.","journal-title":"Front Oncol"},{"issue":"12","key":"2732_CR138","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/1947601911423654","volume":"2","author":"BL Krock","year":"2011","unstructured":"Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2(12):1117\u201333.","journal-title":"Genes Cancer"},{"issue":"10","key":"2732_CR139","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00262-016-1879-5","volume":"65","author":"N Kheshtchin","year":"2016","unstructured":"Kheshtchin N, Arab S, Ajami M, Mirzaei R, Ashourpour M, Mousavi N, et al. Inhibition of HIF-1\u03b1 enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer. Cancer Immunol Immunother. 2016;65(10):1159\u201367.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2732_CR140","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1556\/APhysiol.96.2009.1.2","volume":"96","author":"J Adams","year":"2009","unstructured":"Adams J, Difazio L, Rolandelli R, Lujan J, Hasko G, Csoka B, et al. HIF-1: a key mediator in hypoxia. Acta Physiol Hung. 2009;96(1):19\u201328.","journal-title":"Acta Physiol Hung"},{"issue":"7","key":"2732_CR141","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1172\/JCI0215337","volume":"110","author":"K Synnestvedt","year":"2002","unstructured":"Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5\u2032-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Investig. 2002;110(7):993\u20131002.","journal-title":"J Clin Investig"},{"issue":"11","key":"2732_CR142","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/1535370215584939","volume":"240","author":"X Du","year":"2015","unstructured":"Du X, Ou X, Song T, Zhang W, Cong F, Zhang S, et al. Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells. Exp Biol Med. 2015;240(11):1472\u20139.","journal-title":"Exp Biol Med"},{"issue":"3","key":"2732_CR143","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0002-9440(10)64062-X","volume":"158","author":"C Sundberg","year":"2001","unstructured":"Sundberg C, Nagy JA, Brown LF, Feng D, Eckelhoefer IA, Manseau EJ, et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor\/vascular endothelial growth factor-164 gene delivery. Am J Pathol. 2001;158(3):1145\u201360.","journal-title":"Am J Pathol"},{"issue":"3","key":"2732_CR144","doi-asserted-by":"publisher","first-page":"101042831769502","DOI":"10.1177\/1010428317695021","volume":"39","author":"S Arab","year":"2017","unstructured":"Arab S, Kheshtchin N, Ajami M, Ashurpoor M, Safvati A, Namdar A, et al. Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. Tumor Biol. 2017;39(3):1010428317695021.","journal-title":"Tumor Biol"},{"issue":"3","key":"2732_CR145","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1215\/15228517-2008-001","volume":"10","author":"R Du","year":"2008","unstructured":"Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008;10(3):254\u201364.","journal-title":"Neuro Oncol"},{"issue":"5","key":"2732_CR146","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1007\/s12035-018-1240-4","volume":"56","author":"J Azambuja","year":"2019","unstructured":"Azambuja J, Gelsleichter N, Beckenkamp L, Iser I, Fernandes M, Figueir\u00f3 F, et al. CD73 downregulation decreases in vitro and in vivo glioblastoma growth. Mol Neurobiol. 2019;56(5):3260\u201379.","journal-title":"Mol Neurobiol"},{"issue":"10","key":"2732_CR147","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/jcm8101526","volume":"8","author":"J Wang","year":"2019","unstructured":"Wang J, Matosevic S. NT5E\/CD73 as correlative factor of patient survival and natural killer cell infiltration in glioblastoma. J Clin Med. 2019;8(10):1526.","journal-title":"J Clin Med"},{"issue":"1","key":"2732_CR148","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","volume":"26","author":"S Goswami","year":"2020","unstructured":"Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020;26(1):39\u201346.","journal-title":"Nat Med"},{"issue":"4","key":"2732_CR149","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/10837450.2019.1705485","volume":"25","author":"FC Teixeira","year":"2020","unstructured":"Teixeira FC, Bruxel F, Azambuja JH, Berenguer AM, Stefani MA, S\u00e9vigny J, et al. Development and characterization of CD73-siRNA-loaded nanoemulsion: effect on C6 glioma cells and primary astrocytes. Pharm Dev Technol. 2020;25(4):408\u201315.","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"2732_CR150","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12035-019-01730-6","volume":"57","author":"J Azambuja","year":"2020","unstructured":"Azambuja J, Schuh R, Michels L, Gelsleichter N, Beckenkamp L, Iser I, et al. Nasal administration of cationic nanoemulsions as CD73-siRNA delivery system for glioblastoma treatment: a new therapeutical approach. Mol Neurobiol. 2020;57(2):635\u201349.","journal-title":"Mol Neurobiol"},{"issue":"9","key":"2732_CR151","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00262-020-02569-w","volume":"69","author":"J Azambuja","year":"2020","unstructured":"Azambuja J, Schuh R, Michels L, Iser I, Beckenkamp L, Roliano G, et al. Blockade of CD73 delays glioblastoma growth by modulating the immune environment. Cancer Immunolo Immunother CII. 2020;69(9):1801\u201312.","journal-title":"Cancer Immunolo Immunother CII."},{"issue":"6","key":"2732_CR152","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00280-020-04077-1","volume":"85","author":"J Azambuja","year":"2020","unstructured":"Azambuja J, Schuh R, Michels L, Gelsleichter N, Beckenkamp L, Lenz G, et al. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model. Cancer Chemother Pharmacol. 2020;85(6):1177\u201382.","journal-title":"Cancer Chemother Pharmacol."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02732-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:09:58Z","timestamp":1726153798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02732-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":152,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["2732"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02732-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}